Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

In today’s Health Headlines, June is Myasthenia Gravis Awareness Month. What is myasthenia gravis, how is it diagnosed, and ...

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

MG-ADL scores improved, indicating enhanced daily functioning for patients with myasthenia gravis. Limitations include potential coding errors, selection biases, and missing clinical data ...

MYASTHENIA gravis has frequently been described as a clinical entity. It is a disease characterized by abnormal skeletal-muscle fatigability. The cause is unknown. The myoneural junction seems to ...

"Psychological assessments are essential in the management of myasthenia gravis, as the condition is frequently associated ...

In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 ...